目的 探讨采用复明片联合氨碘肽滴眼液治疗玻璃体混浊患者的临床效果。方法 选取2015年1月—2017年1月监利县人民医院收治的玻璃体混浊患者102例，随机分成对照组和治疗组，每组各51例。对照组给予氨碘肽滴眼液，1滴/次，3次/d；治疗组患者在对照组的基础上口服复明片，5片/次，3次/d。两组患者均连续治疗3月。观察两组患者临床疗效，同时比较治疗前后两组患者玻璃体混浊程度和视力评分。结果 治疗后，对照组和治疗组临床有效率分别为82.35%和96.08%，两组比较差异具有统计学意义（P<0.05）。治疗后，两组患者的玻璃体混浊程度评分显著降低，视力评分显著升高，同组治疗前后比较差异具有统计学意义（P<0.05）；同时治疗后治疗组患者玻璃体混浊程度和视力评分明显优于对照组患者，两组比较差异具有统计学意义（P<0.05）。结论 复明片联合氨碘肽滴眼液治疗玻璃体混浊患者疗效好，不良反应发生率低，具有一定的临床推广应用价值。

Objective To investigate the clinical efficacy of Fuming Tablets combined with Aminopeptin Eye Drops in treatment of vitreous opacity. Methods Patients (102 cases) with vitreous opacity in Jianli County People's Hospital from January 2015 to January 2017 were randomly divided into control and treatment groups, and each group had 51 cases. Patients in the control group were administered with Aminopeptin Eye Drops, 1 drop/time, three times daily. Patients in the treatment group were po administered with Fuming Tablets on the basis of the control group, 5 tablets/time, three times daily. Patients in two groups were treated for 3 months. After treatment, the clinical efficacy was evaluated, and the vitreous opacity and visual acuity scores in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control and treatment groups was 82.35% and 96.08% respectively, and there were differences between two groups (P < 0.05). After treatment, the vitreous opacity scores in two groups were significantly decreased, but the visual acuity scores were significantly increased, and the difference was statistically significant in the same group (P < 0.05). And these scores in the treatment group after treatment were significantly better than those in the control group, with significant difference between two groups (P < 0.05). Conclusion Fuming Tablets combined with Aminopeptin Eye Drops has good clinical effect in treatment of vitreous opacity with lower adverse reactions, which has a certain clinical application value.